These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32196719)

  • 1. Aleukemia cutis: Clinicopathological and molecular investigation of two cases.
    Azari-Yaam A; Safavi M; Ghanadan A
    J Cutan Pathol; 2020 Aug; 47(8):747-754. PubMed ID: 32196719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid sarcoma in a newborn: A rare manifestation of congenital acute myeloid leukemia.
    Mullen B; Sabet K; Jacobs S; Calleroz AT; Habeshian KA; Cheng J
    Pediatr Dermatol; 2023; 40(4):751-752. PubMed ID: 37029447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
    Choschzick M; Bacher U; Ayuk F; Lebeau A
    J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations.
    Han S; Patel T; Garcia ML; Tirado M
    J Cutan Pathol; 2024 Feb; 51(2):130-134. PubMed ID: 37866827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review.
    Elkeeb D; Hopkins Z; Miles RR; Halwani A; Wada D
    Eur J Dermatol; 2018 Dec; 28(6):809-817. PubMed ID: 30698150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat extramedullary acute myeloid leukemia.
    Bakst RL; Tallman MS; Douer D; Yahalom J
    Blood; 2011 Oct; 118(14):3785-93. PubMed ID: 21795742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous myeloid sarcoma: natural history and biology of an uncommon manifestation of acute myeloid leukemia.
    Hurley MY; Ghahramani GK; Frisch S; Armbrecht ES; Lind AC; Nguyen TT; Hassan A; Kreisel FH; Frater JL
    Acta Derm Venereol; 2013 May; 93(3):319-24. PubMed ID: 23165700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis.
    Pina-Oviedo S; Torres-Cabala CA; Miranda RN; Tetzlaff MT; Singh S; Rapini RP; Prieto VG; Aung PP
    Am J Dermatopathol; 2017 May; 39(5):388-392. PubMed ID: 27759701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.
    Peker D; Parekh V; Paluri R; Deal T; Borate U; Di Stasi A; Harada S; Arroyo EA; Reddy V
    Int J Hematol; 2014 Nov; 100(5):457-63. PubMed ID: 25209604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
    Sarvis JA; Auge BK
    Urology; 2009 May; 73(5):1163.e1-3. PubMed ID: 18602141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis.
    Karagounis TK; Rotemberg V; Geskin LJ; Jurcic JG; MDAuthors GN
    Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations.
    von Keudell G; Larson RA
    J Clin Oncol; 2016 May; 34(13):e123-5. PubMed ID: 24733791
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.